Drugs / INR102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06970119 | May 2025 → Jun 2029 expected | prostate cancer | Yunhe Pharmaceutical (Tianjin) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INR102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06970119 ↗ |
| Modality | Other / unclassified | “lutetium-177 (\[177Lu\])-labeled radiopharmaceutical agent” NCT06970119 ↗ |